Preparation And Evaluation Oral Buccal Patches Of Sitagliptin Phosphate As Antidiabetic Drug

The study focuses on the development and evaluation of oral buccal patches containing Sitagliptin Phosphate, an antidiabetic drug, aimed at providing a controlled and effective delivery system for diabetes management. Sitagliptin Phosphate, a widely used DPP-4 inhibitor, was incorporated into buccal patches designed for mucosal absorption, offering a potentially enhanced alternative to conventional oral formulations. The preparation of the buccal patches involved using polymers such as hydroxypropyl methylcellulose (HPMC) and ethyl alcohol to ensure optimal film formation, mechanical strength, and drug release characteristics. Various formulations were evaluated for their physicochemical properties, including drug content, thickness, and uniformity. In vitro drug release studies were conducted to assess the rate and extent of Sitagliptin Phosphate release from the patches. The adhesion properties and mucoadhesion were also examined to ensure effective attachment and sustained drug release at the buccal mucosa. The results demonstrated that the buccal patches could achieve a controlled release profile, with favorable mucoadhesive properties that facilitate prolonged drug contact with the mucosal surface. The patches showed potential for improving patient compliance and therapeutic efficacy by offering an alternative to oral dosing and minimizing first-pass metabolism. This research highlights the feasibility of buccal patches as a novel drug delivery system for Sitagliptin Phosphate, providing a promising approach to enhance the management of diabetes. Further clinical studies are warranted to validate the in vivo performance and therapeutic benefits of this delivery system.